Drug and Medical Device Product Liability DeskbookFDA-regulated products now account for an estimated one-fifth of overall economic activity in the U.S. They have also been the focus of a litigation explosion. This timely guide covers all aspects of litigation involving drugs, medical devices, vaccines and other FDA-regulated prescription products. The Drug and Medical Device Product Liability Deskbook includes: detailed coverage of: warning-related claims and defenses; other information-based theories; strict liability; FDA-related per se liability; preemption of common law tort claims by the Food, Drug & Cosmetic Act and FDA regulations; class actions in drug and medical device litigation; theories of liability asserted against entities other than manufacturers; practical issues involving litigation management; the use of expert witnesses; and many other important topics. The authors include practical coverage of "what a litigator needs to know about the FDA." You'll also find out how plaintiffs and defendants can enhance their chances for success before litigation even commences. Book ʢ looseleaf, one volume, 1,158 pages; published in 2004, updated as needed; no additional charge for updates during your subscription. Looseleaf print subscribers receive supplements. The online edition is updated automatically. ISBN: 978-1-58852-121-7. |
What people are saying - Write a review
Contents
2 Guaranteed Issue In the Small Group | 2-2 |
Market 1616 | 2-16 |
3 Insurers May Use Certain Underwriting | 2-3 |
The Federal Framework | 2-4 |
Requirements to Deny Coverage 1616 | 2-16 |
1 Criteria for an Adequate Warning | 2-1 |
4 Denial of Coverage May Result in | 2-4 |
2 Issues of Fact Concerning Warning | 2-12 |
1 Disability May Arise Within First 60Days | 8-1 |
of COBRA Continuation 1624 | 8-16 |
1 Strict Liability | 8-21 |
3 Informed Consent | 8-21 |
1 Monitoring | 7 |
11 | 7 |
2 Any Disabled Qualified Beneficiary | 9-2 |
Become Entitled to Up to 29 Months COBRA Continuation 1624 | 9-16 |
Suspension of New Business Activity in a Service Area 1617 | 2-16 |
4 Other Causation Issues in Warning Cases 2 0522 | 2-22 |
8 Special Rules Regarding Association | 2-8 |
101 | |
CHAPTER 3 | 2-3 |
Introduction | 2-13 |
Coverage 1618 | 3-16 |
029 | 3-27 |
4 Rebutting Plaintiffs Prima Facie Case | 4 |
1 The Learned Intermediary Rule as | 4-1 |
from the Market 1622 | 4-16 |
Federal Preemption as a Defense to Drug | 5-1 |
5 Federal Preemption of State Insurance | 5-5 |
CHAPTER 6 | 5-52 |
Enhancing Chances for Success | 5-52 |
CHAPTER 8 | 7-16 |
CHAPTER 10 | 9-38 |
3 Newborns and Adopted Children | 10-3 |
Qualified Beneficiaries 1624 | 10-16 |
CHAPTER 11 | 11 |
d Adverse Drug and Medical Device | 11-1 |
4 Coverage Under Another Group | 11-4 |
Health Plan 1625 | 11-16 |
1-1 | |
1-5 | |
1-16 | |
06 LongTerm Care 1628 | xlvi |
1 Federal Tax Treatment of LongTerm Care | 14-1 |
Clarified 1628 | 14-14 |
The Class Action Fairness Act CAFA 7 071 | 18-7 |